Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Amicus Therapeutics
Amicus Therapeutics
Activities:
Research & Development
Finance
Pharmaceutical
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Catalent wins CDMO contract with Amicus Therapeutics
The US biotech company has chosen Paragon Gene Therapy development and manufacturing capability for lysosomal disorder programmes
Manufacturing
Amicus chooses Thermo Fisher for gene therapy CDMO services
Collaboration will focus on the rare genetic cause of Batten disease
Design & Build
Amicus builds global R&D centre for gene therapy in the US
Located in Philadelphia, the new 75,000 sqft facility will be completed in the second half of 2019
Manufacturing
WuXi Biologics inks commercial agreement with Amicus
Chinese biotech company has become exclusive drug substance manufacturing partner and key commercial drug product supplier for Pompe biologic ATB200
Research & Development
Drug licensing deals in 2010
Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Research & Development
GSK and Amicus Therapeutics sign exclusive agreement
To develop and commercialise Amigal for Fabry disease
Subscribe now